The rise of Viagra and its impact on the medicinal landscape presents a intricate question for shareholders. While the early sales data were astounding, the intellectual property has lapsed, leading to a flood of copycat alternatives that are reducing profit. Moreover, the industry is facing challenges related to aging trends and changing healthcar